Analysts Offer Insights on Healthcare Companies: Inovio Pharmaceuticals (NASDAQ: INO) and Perrigo Company plc (NYSE: PRGO)

By Carrie Williams

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Inovio Pharmaceuticals (INOResearch Report) and Perrigo Company plc (PRGOResearch Report).

Inovio Pharmaceuticals (INO)

In a report issued on August 9, Jason McCarthy from Maxim Group maintained a Buy rating on Inovio Pharmaceuticals, with a price target of $6. The company’s shares closed on Friday at $2.49, close to its 52-week low of $2.15.

McCarthy observed:

“Inovio reported 2Q19 with revenue of $136K (grants, collaborations) and a net loss of ($29.4M). The company ended the period with $106M in cash, which does not include the private placement of convertible bonds announced on 8/6 with Korea Investment Partners (KIP) for an additional 18B Korean won (~ $15M).”

According to TipRanks.com, McCarthy has currently no stars on a ranking scale of 0-5 stars, with an average return of -23.5% and a 20.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Hancock Jaffe Laboratories Inc, Aridis Pharmaceuticals Inc, and Achieve Life Sciences Inc.

Inovio Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $10.33, which is a 314.9% upside from current levels. In a report issued on July 26, H.C. Wainwright also reiterated a Buy rating on the stock with a $13 price target.

See today’s analyst top recommended stocks >>

Perrigo Company plc (PRGO)

In a report issued on August 8, Randall Stanicky from RBC Capital maintained a Hold rating on Perrigo Company plc, with a price target of $48. The company’s shares closed on Friday at $46.90.

According to TipRanks.com, Stanicky is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -19.2% and a 22.2% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Amneal Pharmaceuticals Inc, and Aquestive Therapeutics Inc.

Currently, the analyst consensus on Perrigo Company plc is a Moderate Buy with an average price target of $53.67.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.